Anti-inflammatory agents in the management of alimentary mucositis
- 25 March 2006
- journal article
- review article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 14 (6) , 558-565
Abstract
Alimentary mucositis is a significant complication of cancer therapy, with important clinical and economic implications. In June 2005, the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology conducted an evidence-based review of the literature on alimentary mucositis. The goal of this literature review was to update previously published guidelines for the management of mucositis. This article reports the findings of the subgroup charged with reviewing the literature related to anti-inflammatory interventions. Considerable preclinical and clinical evidence suggests that the use of anti-inflammatory agents may be a promising approach to reduce the severity of mucositis. However, there was not enough evidence to support any new guidelines advocating the use of any specific anti-inflammatory intervention. Thus, there is a need for well-designed clinical trials evaluating the use of anti-inflammatory agents in the management of mucositis.Keywords
This publication has 52 references indexed in Scilit:
- Oral Complications and Management Considerations in Patients Treated with High-Dose ChemotherapySupportive Cancer Therapy, 2004
- Oxidative stress contributes to methotrexate-induced small intestinal toxicity in ratsScandinavian Journal of Gastroenterology, 2004
- Effects of TGF‐α gene knockout on epithelial cell kinetics and repair of methotrexate‐induced damage in mouse small intestineJournal of Cellular Physiology, 2002
- Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiationInternational Journal of Radiation Biology, 1999
- Differential Regulation of Cyclooxygenases 1 and 2 by Interleukin-1β, Tumor Necrosis Factor-α, and Transforming Growth Factor-β1 in Human Lung FibroblastsExperimental Cell Research, 1998
- Olsalazine is contraindicated during pelvic radiation therapy: Results of a double-blind, randomized clinical trialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1996
- PROTECTION FROM RADIATION-INDUCED ORAL MUCOSITIS BY MISOPROSTOL, A PROSTAGLANDIN E1 ANALOGAmerican Journal of Therapeutics, 1995
- Allopurinal mouthwashes in methotraxate‐induced stomatitisArthritis & Rheumatism, 1994
- Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositisBritish Journal of Oral and Maxillofacial Surgery, 1990
- Antiinflammatory agents protect opossum esophagus during radiotherapyDigestive Diseases and Sciences, 1982